← Back to Search

Behavioral Intervention

Mindful Attention Training for Pediatric Cancer Survivors

N/A

Recruiting

Led By Courtney L Gallen, Ph.D.

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Normal or corrected-normal vision and hearing

Age 7-17 at the time of enrollment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 8 weeks

Awards & highlights

Study Summary

This trial will test a new training to help with thinking and behavior in kids who have survived cancer.

Who is the study for?

This trial is for children aged 7-17 who have survived pediatric cancer, can follow the study's procedures, and have a guardian to consent. They should speak English fluently, not be on certain cancer treatments that affect participation, and must have had radiation therapy to the brain or neck.Check my eligibility

What is being tested?

The study tests an adaptive attention training program against standard questionnaires to see if it improves thinking skills and behavior in kids who've beaten cancer. It's a pilot study which means it's preliminary research before larger studies.See study design

What are the potential side effects?

Since this trial involves attention training exercises and questionnaires rather than medication, traditional side effects are not expected. However, participants may experience fatigue or frustration related to cognitive tasks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My vision and hearing are normal, or corrected to normal.

Select...

I am between 7 and 17 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants who complete study

Secondary outcome measures

Change in mean performance on a Continuous Performance Task (CPT) over time

Other outcome measures

Change in mean performance on a Delay Discounting Task over time

Change in mean performance on a computerized Math Fluency Test

Change in mean performance on a computerized Reading Fluency Test

+5 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: No Contact Group (Not Randomized)Experimental Treatment1 Intervention

An additional thirty participants will be enrolled separately (not randomized) into the no-contact group. Participants in the no-contact group will not complete any study activities for 6-8 weeks after completing the baseline assessments. After this period, participants will be prompted to log into Nexus to complete end of study assessments (same set of assessments administered/completed at baseline).

Group II: Adaptive Attention TrainingExperimental Treatment2 Interventions

Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.

Group III: Low-dose Adaptive Attention TrainingActive Control2 Interventions

Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Adaptive Attention Training

2019

N/A

~60

Questionnaires

2013

Completed Phase 2

~3330

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,505 Previous Clinical Trials

15,237,485 Total Patients Enrolled

Courtney L Gallen, Ph.D.Principal InvestigatorUniversity of California, San Francisco

Media Library

Novel Mindful Attention Training (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05000905 — N/A

Pediatric Cancer Research Study Groups: Adaptive Attention Training, Low-dose Adaptive Attention Training, No Contact Group (Not Randomized)

Pediatric Cancer Clinical Trial 2023: Novel Mindful Attention Training Highlights & Side Effects. Trial Name: NCT05000905 — N/A

Novel Mindful Attention Training (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05000905 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are seniors aged 75 and above eligible to join this experiment?

"This medical trial only accepts participants aged between 7 and 17, as specified in the eligiblity criteria."

Answered by AI

Who qualifies to partake in this research program?

"This trial is enrolling 40 participants between the ages of 7 and 17 with a history of pediatric cancer. These patients must have: (1) been exposed to radiation therapy in the brain or neck; (2) survived at least 1 year after diagnosis; and, (3) be currently not undergoing treatment."

Answered by AI

Is it possible to join this research experiment at present?

"This trial is not currently recruiting participants, as indicated by information found on clinicaltrials.gov which evidences a posting date of December 1st 2022 and an update made to the page on November 21st 2022. However, there are 54 other medical studies presently welcoming enrollees."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training

2023. "Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05000905.

All > Pediatric Cancer